Simulation of Clinical Trials with Mathematical Models ... - CBI

More documents

Recommendations

Info

30 The effect begins immediately 0.12 Annual risk of four complications or death 0.1 0.08 Nothing ALL HbA1c 0.06 0.04 0.02 0 0 5 10 15 20 25 Time since start of program
31 CMI Independent Evaluation (2007) • In 2004-2005 28% of KP’s eligible study population in northern + southern CA (n=170,024) had received A-L-L at low exposure, 13% at high exposure (59% no exposure) • Modeled results consistent with actual findings by CMI: – By 2006, heart attacks and strokes decreased by 15 per 1000 members for the low exposure group (p
Page 1 and 2: Simulation of Clinical Trials with
Page 3 and 4: Topics • Rationale, mechanisms, a
Page 5 and 6: There are several ways to try to pr
Page 7 and 8: Topics • Rationale, mechanisms, a
Page 9 and 10: 9 Physiological Pathways are Repres
Page 11 and 12: 11 The Model is clinically and admi
Page 13 and 14: Over 50 trials have been used to va
Page 15 and 16: The Model can enhance trial design,
Page 17 and 18: Only simulation modeling could have
Page 19 and 20: 19 This enabled generation of longi
Page 21 and 22: In simulation, the DPP trial was si
Page 23 and 24: Estimating longitudinal cost outcom
Page 25 and 26: Simulation enabled trial expansion
Page 27 and 28: A-L-L: Clinical trial simulation en
Page 29: 29 A-L-L has a bigger effect than 1
Page 33 and 34: A population dataset with pre-run i
Page 35 and 36: Health and cost outcomes can be cap
Page 37 and 38: Appendix www.archimedesmodel.com ..
Page 39 and 40: Publications • Age at initiation
Page 41 and 42: 41 The validation approach is rigor
Page 43 and 44: Fraction of patients 43 The Model y
Page 45 and 46: In the DPP simulation, populations
Page 47 and 48: Cost/ QALY DPP simulation also enab
Page 49 and 50: A-L-L: The savings begin immediatel

Simulation of Clinical Trials with Mathematical Models ... - CBI

Create successful ePaper yourself

Delete template?

Save as template?